These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 31218831)

  • 1. Tip60-dependent acetylation of KDM2B promotes osteosarcoma carcinogenesis.
    Shi X; Fan M
    J Cell Mol Med; 2019 Sep; 23(9):6154-6163. PubMed ID: 31218831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p300 Acetylates JHDM1A to inhibit osteosarcoma carcinogenesis.
    Wang Y; Sun B; Zhang Q; Dong H; Zhang J
    Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):2891-2899. PubMed ID: 31307234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CBP-triggered KDM2B acetylation accelerates the carcinogenesis of colon cancer.
    Qi Y; Zhao Y
    J Cell Physiol; 2020 Mar; 235(3):2901-2910. PubMed ID: 31531877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone demethylase KDM2B promotes triple negative breast cancer proliferation by suppressing p15INK4B, p16INK4A, and p57KIP2 transcription.
    Zheng Q; Fan H; Meng Z; Yuan L; Liu C; Peng Y; Zhao W; Wang L; Li J; Feng J
    Acta Biochim Biophys Sin (Shanghai); 2018 Sep; 50(9):897-904. PubMed ID: 30060056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of microRNA let-7b expression by KDM2B promotes cancer progression by targeting EZH2 in ovarian cancer.
    Kuang Y; Xu H; Lu F; Meng J; Yi Y; Yang H; Hou H; Wei H; Su S
    Cancer Sci; 2021 Jan; 112(1):231-242. PubMed ID: 33091189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KDM2A promotes lung tumorigenesis by epigenetically enhancing ERK1/2 signaling.
    Wagner KW; Alam H; Dhar SS; Giri U; Li N; Wei Y; Giri D; Cascone T; Kim JH; Ye Y; Multani AS; Chan CH; Erez B; Saigal B; Chung J; Lin HK; Wu X; Hung MC; Heymach JV; Lee MG
    J Clin Invest; 2013 Dec; 123(12):5231-46. PubMed ID: 24200691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KDM2B is a histone H3K79 demethylase and induces transcriptional repression via sirtuin-1-mediated chromatin silencing.
    Kang JY; Kim JY; Kim KB; Park JW; Cho H; Hahm JY; Chae YC; Kim D; Kook H; Rhee S; Ha NC; Seo SB
    FASEB J; 2018 Oct; 32(10):5737-5750. PubMed ID: 29763382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alternative isoforms of KDM2A and KDM2B lysine demethylases negatively regulate canonical Wnt signaling.
    Lađinović D; Pinkas D; Šopin T; Raška O; Liška F; Raška I; Vacík T
    PLoS One; 2020; 15(10):e0236612. PubMed ID: 33104714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KDM2B is involved in the epigenetic regulation of TGF-β-induced epithelial-mesenchymal transition in lung and pancreatic cancer cell lines.
    Wanna-Udom S; Terashima M; Suphakhong K; Ishimura A; Takino T; Suzuki T
    J Biol Chem; 2021; 296():100213. PubMed ID: 33779563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SRF is a nonhistone methylation target of KDM2B and SET7 in the regulation of skeletal muscle differentiation.
    Kwon DH; Kang JY; Joung H; Kim JY; Jeong A; Min HK; Shin S; Lee YG; Kim YK; Seo SB; Kook H
    Exp Mol Med; 2021 Feb; 53(2):250-263. PubMed ID: 33564100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KDM2B, an H3K36-specific demethylase, regulates apoptotic response of GBM cells to TRAIL.
    Kurt IC; Sur I; Kaya E; Cingoz A; Kazancioglu S; Kahya Z; Toparlak OD; Senbabaoglu F; Kaya Z; Ozyerli E; Karahüseyinoglu S; Lack NA; Gümüs ZH; Onder TT; Bagci-Onder T
    Cell Death Dis; 2017 Jun; 8(6):e2897. PubMed ID: 28661478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The KDM2B- let-7b -EZH2 axis in myelodysplastic syndromes as a target for combined epigenetic therapy.
    Karoopongse E; Yeung C; Byon J; Ramakrishnan A; Holman ZJ; Jiang PY; Yu Q; Deeg HJ; Marcondes AM
    PLoS One; 2014; 9(9):e107817. PubMed ID: 25225797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Positional cloning and comprehensive mutation analysis identified a novel KDM2B mutation in a Japanese family with minor malformations, intellectual disability, and schizophrenia.
    Yokotsuka-Ishida S; Nakamura M; Tomiyasu Y; Nagai M; Kato Y; Tomiyasu A; Umehara H; Hayashi T; Sasaki N; Ueno SI; Sano A
    J Hum Genet; 2021 Jun; 66(6):597-606. PubMed ID: 33402700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lysine demethylase 2B regulates angiogenesis via Jumonji C dependent suppression of angiogenic transcription factors.
    Sasaki Y; Higashijima Y; Suehiro JI; Sugasawa T; Oguri-Nakamura E; Fukuhara S; Nagai N; Hirakawa Y; Wada Y; Nangaku M; Kanki Y
    Biochem Biophys Res Commun; 2022 May; 605():16-23. PubMed ID: 35306360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transcriptional regulation of amino acid metabolism by KDM2B, in the context of ncPRC1.1 and in concert with MYC and ATF4.
    Chavdoula E; Anastas V; La Ferlita A; Aldana J; Carota G; Spampinato M; Soysal B; Cosentini I; Parashar S; Sircar A; Nigita G; Sehgal L; Freitas MA; Tsichlis PN
    Metabolism; 2024 Jan; 150():155719. PubMed ID: 37935302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic factor siRNA screen during primary KSHV infection identifies novel host restriction factors for the lytic cycle of KSHV.
    Naik NG; Nguyen TH; Roberts L; Fischer LT; Glickman K; Golas G; Papp B; Toth Z
    PLoS Pathog; 2020 Jan; 16(1):e1008268. PubMed ID: 31923286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KDM2B/FBXL10 targets c-Fos for ubiquitylation and degradation in response to mitogenic stimulation.
    Han XR; Zha Z; Yuan HX; Feng X; Xia YK; Lei QY; Guan KL; Xiong Y
    Oncogene; 2016 Aug; 35(32):4179-90. PubMed ID: 26725323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Epigenetic Factor KDM2B Regulates EMT and Small GTPases in Colon Tumor Cells.
    Zacharopoulou N; Tsapara A; Kallergi G; Schmid E; Alkahtani S; Alarifi S; Tsichlis PN; Kampranis SC; Stournaras C
    Cell Physiol Biochem; 2018; 47(1):368-377. PubMed ID: 29772566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MiR-448 promotes glycolytic metabolism of gastric cancer by downregulating KDM2B.
    Hong X; Xu Y; Qiu X; Zhu Y; Feng X; Ding Z; Zhang S; Zhong L; Zhuang Y; Su C; Hong X; Cai J
    Oncotarget; 2016 Apr; 7(16):22092-102. PubMed ID: 26989077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KDM2b/JHDM1b, an H3K36me2-specific demethylase, is required for initiation and maintenance of acute myeloid leukemia.
    He J; Nguyen AT; Zhang Y
    Blood; 2011 Apr; 117(14):3869-80. PubMed ID: 21310926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.